Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-01-16
2007-01-16
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C560S129000
Reexamination Certificate
active
10723140
ABSTRACT:
The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
REFERENCES:
patent: 3956284 (1976-05-01), Hess et al.
patent: 3962312 (1976-06-01), Hayashi et al.
patent: 3987087 (1976-10-01), Bundy
patent: 4001300 (1977-01-01), Axen
patent: 4011262 (1977-03-01), Hess et al.
patent: 4115586 (1978-09-01), Miller, Jr.
patent: 4116988 (1978-09-01), Nelson
patent: 4117119 (1978-09-01), Kurono et al.
patent: 4128713 (1978-12-01), Schneider
patent: 4131738 (1978-12-01), Smith
patent: 4599353 (1986-07-01), Bito
patent: 4820728 (1989-04-01), Collins et al.
patent: 4824857 (1989-04-01), Goh et al.
patent: 4883819 (1989-11-01), Bito
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5057621 (1991-10-01), Cooper et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5166178 (1992-11-01), Ueno et al.
patent: 5194429 (1993-03-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz
patent: 5321128 (1994-06-01), Stjernschantz
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5422369 (1995-06-01), Stjernschantz
patent: 6030999 (2000-02-01), Stjernschantz
patent: 6187813 (2001-02-01), Stjernschantz
patent: 573018 (1986-02-01), None
patent: 600168 (1990-08-01), None
patent: 986926 (1976-04-01), None
patent: 2234709 (1973-02-01), None
patent: 170258 (1986-02-01), None
patent: 242580 (1987-10-01), None
patent: 253094 (1988-01-01), None
patent: 238135 (1988-08-01), None
patent: 281239 (1988-09-01), None
patent: 289349 (1988-11-01), None
patent: 308135 (1989-03-01), None
patent: 364417 (1990-04-01), None
patent: 366279 (1990-05-01), None
patent: 455264 (1991-11-01), None
patent: 1324737 (1973-07-01), None
patent: WO90/02553 (1990-03-01), None
Boeckman et al. “Synthesis of Mugineic Acid through Direct C-Acylation Using Diphenyl Phosphorazidate” J. Org. Chem. 1986, 5489-5490.
Beitch et al. “The effects of prostaglandins on the intraocular pressure of the rabbit” Br. J. Pharmac. 1969, 158-167.
Bill A (1975) “Blood Circulation and fluid dynamics in the eye”.Physiol. Rew. 55: 383-417.
Bito LZ, Draga A, Blanco DJ, Camras CB (1983) “Long Term Maintenzance of Reduced intraocular Pressure by Daily or Twice Daily Topical Application of Prostaglandins to Cat or Rhesus Monk,ey Eyes”Invest. Ophthalmol. Vis. Sci. 24: 312-319.
Bito, Baroody and Miranda (1987): Eicosandoids as a new class of ocular Hypoterisive agents. The apparent therapeutic advantage of derived Prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D types, Experimental Eye Research, 44:825.
Bito LZ, Camras CB, Gum GG and Resul B (1989). “The Ocular Hypotensive Effects and Side Effects of Prostaglandins on the Eyes of Experimental Animals”Progress in Clinical and Biological Research312 Ed. LZ Bito and Johan Stjernschantz, A.R. Liss, Inc., New York.
Burke et l., Prostaglandin F2αEffects on Rabbit IOP Negatively Correlate with Classical PGF2α-Receptor Stimulation Presented at ARVO annual meeting in Florida May 1-6, 1988.
Bundy, Chem Abst. 90:168141d, 1979.
Camras CB, Bito LZ (1981). Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α.Curr Eye Res1:205-209.
Camras, CB, Podos SM, Rosenthal JS, Lee PY, Severin CH (1987a). Multiple dosing of prostaglandin F2αor epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics.Invest Ophthalmol Vis Sci28:463-469.
Camras C B, Bito L Z and Eakins K E (1977): “Reduction of intraocular pressure by prostaglandins applied to the eyes of concious rabbits”, Invest Ophthalmol Vis. Sci, 16:1125.
Camras CB, Bhuyan KC, Podos SM, Bhuyan DK Master RWP (1987b) “Multiple Dosing of Prostaglandin F2αor epinephrine on cynomologus mokey eyes. II. Slitlamp biomicroscopy, aqueous humor analysis, and fluorescein angiography.” Invest. Ophthalmol. Vis. Sci. 28: 921-926.
Camras CB, Siebold EC, Lustgarten JS, Serle JB, Frisch SC, Podos SM, Bito LZ (1988) “Reduction of IOP by prostaglandin F2α-1-isopropyl ester topically applied in glaucoma patients”,Ophthalmology95(Suppl.) 129 [This article is referrenced in the specification, and was raised as prior art in an opposition to Australian patent application 625096, which is related to the instant application. However, we have been unable to locate a copy of this article.]
Crawford K, Kaufman PL and True Gabel, BA (1987), “Pilocarpine antagonizes PGF2α-induced ocular hypotension: Evidence for enhancement of uveoscleral outflow of PGF2α.”Invest. Ophthalmol. Vis. Sci. (Supp.) ARVO Abstract 11.
Crawford, K and Kaufman, P.L., (1987) “Pilocarpine Antagonizes Prostaglandin F2α-Induced Ocular Hypotension in Monkeys” Arch. Ophthamology 105 1112.
Flach AJ, Elisason JA (1988). Topical prostaglandin E2effects on normal human intraocular pressure.J. Ocu. Pharmacol. 4:13-18.
Gabelt, B. and Kaufman, P.L., (1989)“Prostaglandin F2αIncreases Uvelscleral Outflow in the Cynomologus Monkey”, Exp. Eye Res. 49 389-402.
Giuffreé G. (1985). “The effects of prostaglandin F2αin the human eye.”Graefes Arch Clin. Exp. Ophthalmol. 222:139-141.
Goldberg I, Kolker A.E., Kass M.A. and Becker B (1980) “Dipivefrin: current concepts”, Australia J. Ophthalmol., 8:147.
Granstrom, E., (1975) “Metabolism of 17-Phenyl-18,19,20-Trinor-Prostaglandin F2αin the Cynomolgus Monkey and the Human Female”,Prostaglandins9:19-45.
Kass, M.A., Posos, S.M., Moses, R.A., and Becker B. (1972): Prostaglandin E1 and aqueous humor dynamics, Invest Ophthalmol. 11:1022.
Kass M.A., Mandell AI, Goldberg I, Paine J.M. and Becker B (1979) “Dipivefrin and epinephrine treatment of elevated intraocular pressure: A comparative study”, Arch Ophthalmol. 97:1865.
Kaufman PL (1986). “Effects on intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle.”Exp. Eye Res. 43:819-827.
Kerstetter J R, Brubaker R F, Wilson S E and Kullerstrand B S (1987): “Prostaglandin F2 alpha 1-isopropyl ester effects on aqueous humor dynamics in human subjects”, Invest Ophthalmol Vis Sci Suppl, 28:266.
Kerstetter J R, Brubaker R F, Wilson S E and Kullerstrand L (1988) “Prostaglandin F2α-1- Isopropylester Lowers Intracolor Pressure Without Decreasing Aqueous Humor Flow”. Am. J. Ophthalmology 105:30-34.
Kirk-Othmar “Encyclopedia of Chemical Technology”, 3d Ed. Supplement vol. 711-752 (1984).
Lee, P-Y, Shae H, XZu L, Qu C-K (1988). The effect of prostaglandin F2αon intraocular pressure in normotensive human subjects.Invest. Ophthalmol. Vis. Sci. 29:1474-1477.
Miller, “Biological Activities of 17-phenyl-18,19,20-trinorprostaglandins”,Prostaglandins9 9-18 (1975).
Nilsson SFE, Stjernschantz J and Bill A (1987) PGF2αincrease uveoscleral outflow.Invest. Ophthalmol Vis. Sci. Suppl. 284.
Ritch, Shields and Krupin (1989): “The Glaucomas”, C V Mosby, p. 561.
Starr, M.S. (1971) Further studies on the effect of prostaglandin on intraocular pressure in the rabit, Exp. Eye, Res. 11:170.
Villumsen J, Alm A, Soderstrom M, (1989) “Prostaglandin F2α-isopropylester Eye Drops: Effect on Intraocular Pressure in Open Angle Glaucoma”. Brit. J. Ophthalmology 73, 975-79.
Villumsen J. Alm A (1989) “Prostaglandin F2αisopropylester eye drops. Effects in normal human eyes.”Br. J. Ophthalmol. 73:419-426.
Villumsen J and Alm A (1987): “The effect of prostaglandin F2α eye drops in ope
Resul Bahram
Stjernschantz Johan Wilhelm
Kosack Joseph R.
Pharmacia Aktiebolag
Robinson Edward D.
Zielinski Bryan C.
LandOfFree
Prostagladin derivatives for the treatment of glaucoma or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostagladin derivatives for the treatment of glaucoma or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostagladin derivatives for the treatment of glaucoma or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788443